Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
YM155 plus docetaxel in unresectable stage III or stage IV melanoma
2009-015738-31Phase 2Completed
- Sponsor
- Astellas Pharma
- Start
- Oct 2009
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sepantronium and docetaxel in melanoma, sponsored by Astellas Pharma. Primary endpoint: Progression-free survival at 6 months. Started Oct 2009; status: completed.
02
Drugs
sepantroniumdocetaxel
03
Conditions
melanoma
Beyond the preview
Go deeper on 2009-015738-31.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-015738-31.